What Axio Biosolutions does
Founded in 2008, Axio Biosolutions operates in Health Tech industry. Initially focused on creating hemostatic solutions, the company has expanded its product offerings to serve both trauma and surgical care markets. Axio Biosolutions launched MaxioCel, an advanced chitosan-based wound care product, enhancing its portfolio for chronic wound management. Further extending its reach, the company expanded its operations to South America and the Middle East. Competing with companies such as Consure Medical and Zoplar.
Who runs it
Funding and finances
Why this matters to you: funding stage is a rough proxy for how long the runway is and how much structure to expect. It is not a promise, and a profitable bootstrapped company can be the safer bet.
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about Axio Biosolutions yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.